Skip to main content
Jie Wang, MD, Oncology, Philadelphia, PA

JieWangMD

Oncology Philadelphia, PA

Hematologic Oncology

Physician

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd

    Philadelphia, PA 19104
    Phone+1 215-662-4000
    Fax+1 734-647-9443

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2014 - 2017
  • University of Michigan
    University of MichiganResidency, Internal Medicine, 2010 - 2013
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2018 - 2025
  • PA State Medical License
    PA State Medical License 2014 - 2018
  • MI State Medical License
    MI State Medical License 2010 - 2017

Publications & Presentations

PubMed

Press Mentions

  • Jim’s Journey: The Power of Collaboration in Blood Cancer Care
    Jim’s Journey: The Power of Collaboration in Blood Cancer CareOctober 24th, 2024
  • Alpha Biopharma Announces Completion of Its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases
    Alpha Biopharma Announces Completion of Its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System MetastasesAugust 25th, 2022
  • Innovent Release Phase 1 Results of IBI322 (Anti-PD-L1/CD47 Bispecific Antibody) in Patients with Advanced Solid Tumors at AACR Annual Meeting 2022
    Innovent Release Phase 1 Results of IBI322 (Anti-PD-L1/CD47 Bispecific Antibody) in Patients with Advanced Solid Tumors at AACR Annual Meeting 2022April 11th, 2022
  • Join now to see all